Omalizumab in patients with severe asthma: the XCLUSIVE study
| Autor: | Christian Schumann, Stefan Rüdiger, Thomas Wibmer, Kathrin M. Stoiber, Wolfgang Rottbauer, Claus Kroegel, Cornelia Kropf, A. Thielen |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Pulmonary and Respiratory Medicine
Pediatrics medicine.medical_specialty Exacerbation biology business.industry Omalizumab Immunoglobulin E Clinical trial Asthma Control Questionnaire Internal medicine Severity of illness medicine biology.protein Immunology and Allergy Young adult Prospective cohort study business Genetics (clinical) medicine.drug |
| Zdroj: | The Clinical Respiratory Journal. 6:215-227 |
| ISSN: | 1752-6981 1752-699X |
| DOI: | 10.1111/j.1752-699x.2011.00263.x |
| Popis: | Background and Aims: Although the efficacy and safety of omalizumab (OMA) in uncontrolled severe allergic asthma has been demonstrated in several randomised controlled trials (RCTs), information on the treatment in a practice-related setting is limited. Thus, the purpose of this prospective multi-centre study (XCLUSIVE) was to investigate the efficacy, compliance and utilisation of OMA therapy in real-life clinical practice in Germany. Methods: One hundred ninety-five asthmatic patients initiated on anti-Immunoglobulin E (IgE) IgE treatment were followed-up for 6 months. Forced expiratory volume in 1 s (FEV1), exacerbation rate, days of absence, asthma symptoms [Asthma Control Questionnaire (ACQ)], a Global Evaluation of Treatment Effectiveness (GETE) and medication use were assessed. Results: Measured outcome variables improved after a 16-week treatment period with OMA (FEV1+13.7% predicted P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|